A Facebook post covers what GLP-1 weight loss drugs can mean for people booked in for a gastroscopy or colonoscopy.
Recap by typeshit. Post by Facebook on Facebook.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Trial patients lost up to 25% of body weight on the top dose, while Lilly warns that any retatrutide sold outside its trials is illegal and unverified.
The obesity doctor argues the oral Wegovy pill could bring new patients into treatment rather than just pulling users away from injectable GLP-1s.
Loading…